Diabetic ketoacidosis: Difference between revisions

(Strip excess bold)
 
(9 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Adult top}} [[diabetic ketoacidosis (peds)]]
==Background==
==Background==
*Patients in DKA are almost always K+ depleted despite initially fairly normal K+.
*{{AdultPage|diabetic ketoacidosis (peds)}}
**This is due to extracellular shift of K+ due to acidosis as well as insulin infusion, which increases uptake of K+ intracellularly.
 
 
*Diabetic ketoacidosis (DKA) is a life-threatening hyperglycemic emergency characterized by '''hyperglycemia''' (or euglycemia in ~10%), '''metabolic acidosis''', and '''ketonemia'''
*Hospital admissions for DKA have increased substantially over the past decade<ref name="ADA2024">Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47(8):1257-1275.</ref>
*Patients in DKA are almost always K⁺ depleted despite initially normal or elevated serum K⁺
**Extracellular shift of K⁺ occurs due to acidosis, hyperosmolality, and insulin deficiency
**Insulin infusion drives K⁺ back intracellularly → can unmask severe total body K⁺ depletion


===Epidemiology===
===Epidemiology===
*Mortality rate approximately 2-5%<ref>Lebovitz HE: Diabetic ketoacidosis.  Lancet 1995; 345: 767-772.</ref>
*Inpatient DKA mortality: approximately 0.2% in type 1 diabetes and 1.0% in type 2 diabetes<ref name="ADA2024"/>
*DKA can occur in both type 1 and type 2 diabetes (up to 50% of DKA admissions are T2D in some series)
*~6-21% of adults with T1D present with DKA as their initial diagnosis<ref name="ADA2024"/>
*Recurrent DKA is common and often driven by insulin omission due to cost, mental health, substance use, or social determinants — the ED is an opportunity to screen and connect to resources<ref name="ADA2024"/>


===Pathophysiology===
===Pathophysiology===
''Defining features include '''hyperglycemia''' (glucose > 200mg/dl), '''acidosis''' (pH < 7.3), and '''ketonemia'''''
''Defining features include hyperglycemia (glucose >200 mg/dL, or any glucose in a patient with known diabetes), acidosis (pH <7.3 or HCO₃ <18), and ketonemia (BHB ≥3 mmol/L)''<ref name="ADA2024"/>


====[[Hyperglycemia]]====
====[[Hyperglycemia]]====
*Leads to osmotic diuresis and depletion of electrolytes including sodium, potassium, magnesium, calcium and phosphorus.
*Leads to osmotic diuresis and depletion of electrolytes including sodium, potassium, magnesium, calcium, and phosphorus
*Further dehydration impairs glomerular filtration rate (GFR) and contributes to acute renal failure
*Further dehydration impairs GFR and contributes to [[acute kidney injury]]
*Hypokalemia may inhibit insulin release
*Hypokalemia may inhibit insulin release
*Euglycemic DKA (~10% of cases): glucose <200 mg/dL with metabolic acidosis and ketonemia — seen with [[SGLT-2 inhibitors]], pregnancy, low carbohydrate intake, fasting, or recent insulin use<ref name="Peters2015">Peters AL et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687-1693.</ref>


====[[Acidosis]]====
====[[Acidosis]]====
*Due to insulin deficiency -> lipolysis / accumulation of of ketoacids (represented by increased anion gap)
*Due to insulin deficiency lipolysis accumulation of ketoacids (represented by increased anion gap)
*Compensatory respiratory alkalosis (i.e. tachypnea and hyperpnea - Kussmaul breathing)
*Compensatory respiratory alkalosis (tachypnea/hyperpnea Kussmaul breathing)
*Breakdown of adipose creates first acetoacetate leading to conversion to beta-hydroxybutyrate
*Breakdown of adipose creates first acetoacetate, then conversion to beta-hydroxybutyrate (the predominant ketone in DKA)


====[[Dehydration]]====
====[[Dehydration]]====
*Causes activation of RAAS in addition to the osmotic diuresis
*Causes activation of RAAS in addition to osmotic diuresis
*The initial serum values for electrolytes such as K+ may be higher than actual body stores
*Average fluid deficit: 3-6 liters in adults (100 mL/kg)
*Initial serum values for electrolytes (especially K⁺) may be higher than actual total body stores
*Cation loss (in exchange for chloride) worsens metabolic acidosis
*Cation loss (in exchange for chloride) worsens metabolic acidosis


Line 29: Line 39:


==Differential Diagnosis==
==Differential Diagnosis==
===Causes of DKA===
===Causes of DKA (Precipitants)===
*[[Insulin]] or oral hypoglycemic medication non-compliance (or insulin pump malfunction)
''Search for a precipitant in every DKA patient — it changes management''
*Infection
 
*[[Cardiac Ischemia]]  
*Infection (most common precipitant worldwide, 14-58% of cases)<ref name="ADA2024"/>
*Intra-abdominal infections
*Insulin noncompliance/omission — most common in T1D; ask about cost, access, mental health, pump malfunction
*[[Steroid]] use
*[[Acute coronary syndrome|Cardiac ischemia / MI]]
*[[ETOH Abuse]]  
*[[CVA|Stroke]]
*[[Pancreatitis]]
*[[PE|Pulmonary embolism]]
*[[SGLT-2 inhibitors]] (euglycemic DKA)
*[[Pregnancy]] (higher risk of euglycemic DKA)
*[[Steroid]] use (new or dose escalation)
*[[Alcoholic Ketoacidosis|Alcohol use]]
*[[Toxicologic exposure]]
*[[Toxicologic exposure]]
*[[Pregnancy]]  
*[[Hyperthyroidism]] / [[thyroid storm]]
*[[Hyperthyroidism]]  
*[[GI Hemorrhage]]
*[[GI Hemorrhage]]
*[[CVA]]
*[[PE]]
*[[Pancreatitis]]
*[[Renal Failure]]
*[[Renal Failure]]
*[[GI Bleed]]
*New-onset diabetes (DKA as initial presentation)
*[[Alcoholic Ketoacidosis]]
*Insulin pump malfunction (kink, disconnection, site infection, battery failure)
*[[SGLT-2 inhibitors]] (euglycemic DKA)
*Substance use (cocaine, methamphetamine)
*Trauma


{{Hyperglycemia DDX}}
{{Hyperglycemia DDX}}
Line 52: Line 65:
==Evaluation==
==Evaluation==
===Workup===
===Workup===
''Workup to confirm diagnosis and search for possible inciting causes (e.g. infection, [[ACS]])''
''Workup to confirm diagnosis, assess severity, and search for precipitating cause (e.g., infection, [[ACS]])''
*CBC
*BMP (glucose, BUN/Cr, Na⁺, K⁺, Cl⁻, HCO₃⁻, anion gap)
*BMP
*Blood glucose (and bedside point-of-care glucose)
*Blood glucose
*Beta-hydroxybutyrate (BHB) — preferred ketone marker for diagnosis, severity assessment, and monitoring resolution; ideally point-of-care<ref name="ADA2024"/>
*Serum ketones (e.g. beta-hydroxybutyrate and/or acetone)
*[[VBG]] (arterial blood gas is rarely needed)
*Mag
*Magnesium, phosphorus, calcium
*Phos
*CBC (leukocytosis is common in DKA even without infection — >25,000 or left shift more suggestive of infection)
*[[VBG]]/[[ABG]]
*[[ECG]] — evaluate for [[hyperkalemia]]/[[hypokalemia]], ischemia, arrhythmia
*Consider [[ECG]], [[urinalysis]], [[chest X-ray]], [[blood cultures]]
*[[Urinalysis]] — ketonuria may be a useful screen but serum BHB is preferred (see below)
*[[CXR]] — if infection suspected
*[[Blood cultures]] — if concern for sepsis or bacteremia
*Lipase — if concern for [[pancreatitis]]
*[[Lactate]] — if concern for sepsis or tissue hypoperfusion
*Troponin — if chest pain or concern for ACS (interpret with caution in CKD)
*Pregnancy test — in all women of childbearing age
*[[HbA1c]] — helpful in assessing chronic glycemic control and distinguishing new-onset T1D from poorly controlled known diabetes


===Diagnosis===
===Diagnosis===
''Diagnosis is made based on the presence of '''acidosis''' (e.g. venous pH < 7.3 or HCO3 <18) and '''ketonemia''' (e.g. >3mmol/L BOH or ketonuria) in the setting of diabetes (e.g. glucose >200mg/dl)'' <ref>Glaser N, Fritsch M, Priyambada L, et al. ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 2022; 23:835.</ref>
''Diagnosis is made based on the presence of acidosis AND ketonemia in the setting of diabetes''<ref name="ADA2024"/>
 
====Basic Laboratory Findings====
*Blood Glucose
**Capillary blood sugar >200mg/dL
**Blood sugar may not be very elevated if there is impaired gluconeogenesis (eg liver failure, severe alcoholism) or patient is taking a [[SGLT-2 Inhibitor]] <ref>Peters AL et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 2015 Sep; 38(9): 1687-1693.</ref>
*Elevated [[Anion Gap]]
**Bicarb may be normal due to compensatory and contraction alkalosis so the elevated anion gap or ketonuria may be the only clues to the DKA
*Serum ketones
**Beta hydroxybutyrate will be elevated


====Blood Gas====
====2024 ADA/EASD Consensus Diagnostic Criteria====
''No need to perform Arterial blood gas. Venous blood gas is sufficient<ref>Ma OJ, Rush MD, Godfrey MM, Gaddis G. Arterial blood gas results rarely influence emergency physician management of patients</ref>''
{| class="wikitable"
*Difference in pH from VBG vs ABG  will be ±0.02pH units<ref>Kelly AM et al. Review Article – Can Venous Blood Gas Analysis Replace Arterial in Emergency Medical Care. Emery Med Australas 2010; 22: 493 – 498.</ref><ref>Ma OJ et al. Arterial Blood Gas Results Rarely Influence Emergency Physician Management of Patients with Suspected Diabetic Ketoacidosis. Acad Emerg Med Aug 2003; 10(8): 836 – 41. </ref> <ref name="British DKA">Savage MW, Datary KK, Culvert A, Ryman G, Rees JA, Courtney CH, Hilton L, Dyer PH, Hamersley MS; Joint British Diabetes Societies.  Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011 May;28(5):508-15.</ref><ref>Gokel Y, et al. Comparison of Blood Gas and Acid-Base Measurements in Arterial and Venous Blood Samples in Patients with Uremic Acidosis and Diabetic Ketoacidosis in the Emergency Room.  American Journal of Nephrology 2000; 20:319-323.</ref>
|-
! Criterion !! Diagnostic Threshold
|-
| '''Glucose''' || >200 mg/dL (11.1 mmol/L) '''OR''' known history of diabetes (glucose cutoff removed for known diabetics)
|-
| '''pH''' || <7.3 (venous)
|-
| '''Bicarbonate''' || <18 mEq/L
|-
| '''Beta-hydroxybutyrate''' || ≥3.0 mmol/L (preferred), or significant ketonuria if BHB unavailable
|}


====Urinary analysis (ketonuria)====
====Severity Classification====
*[[Urinalysis]] may be a useful screening test early in DKA, if serum ketones not available
{| class="wikitable"
**However, may give a false negative for ketones later in DKA, as acetoacetate is converted to beta-hydroxybutyrate the urinary ketones may turn negative<ref>Stojanovic, V. Sherri Ihle. Role of beta-hydroxybutyric acid in diabetic ketoacidosis: A review. Can Vet J. 2011 Apr; 52(4): 426–430. </ref>
|-
! !! '''Mild''' !! '''Moderate''' !! '''Severe'''
|-
| '''pH''' || 7.25-7.30 || 7.00-7.24 || <7.00
|-
| '''Bicarbonate''' || 15-18 mEq/L || 10-14.9 mEq/L || <10 mEq/L
|-
| '''BHB''' || 3.0-5.9 mmol/L || 6.0-9.9 mmol/L || ≥10.0 mmol/L
|-
| '''Mental status''' || Alert || Alert/drowsy || Stupor/coma
|}


====End Tidal CO2====
====Key Laboratory Pearls====
''Strongly consider capnography for respiratory distress<ref>Nagler J et al. Capnography: A valuable tool for airway management. Emerg Med Clin North Am, 26(4):881, Nov 2008.</ref>''
*Blood Gas: VBG is sufficient — pH difference from ABG is ±0.02 units<ref>Kelly AM et al. Review Article – Can Venous Blood Gas Analysis Replace Arterial in Emergency Medical Care. Emerg Med Australas. 2010;22:493-498.</ref><ref>Ma OJ et al. Arterial Blood Gas Results Rarely Influence Emergency Physician Management of Patients with Suspected Diabetic Ketoacidosis. Acad Emerg Med. 2003;10(8):836-41.</ref>
*ETCO2 can be used for bedside assessment of DKA in pts with glucose>550<ref>Chebl BR, Madden B, Belsky J, et al. Diagnostic value of end tidal capnography in patients with hyperglycemia in the emergency department. BCM Emerg Med. 2016; 16 (1).</ref>
*Urinary ketones: May give a false negative later in DKA — the urine dipstick detects acetoacetate, not beta-hydroxybutyrate. As DKA worsens, the ratio shifts toward BHB, so urine ketones may paradoxically appear negative in severe DKA<ref>Stojanovic V, Ihle S. Role of beta-hydroxybutyric acid in diabetic ketoacidosis: A review. Can Vet J. 2011;52(4):426-430.</ref>
**An ETCO2 of ≥35 is 100% sensitive to rule out DKA
*Bicarb may be normal despite DKA due to compensatory/contraction alkalosis — the elevated anion gap or BHB may be the only clues
**An ETCO2 of ≤21 is 100% specific to diagnosis DKA
*Corrected sodium: Na⁺ decreases by ~1.6 mEq/L for every 100 mg/dL increase in glucose above 100 (some use 2.4 mEq/L per 100 mg/dL for glucose >400). The corrected sodium should rise as glucose falls during treatment — if it is falling, suspect excessive free water administration (risk of cerebral edema)
*ETCO₂: An ETCO₂ ≥35 mmHg is 100% sensitive to rule out DKA; an ETCO₂ ≤21 mmHg is 100% specific for DKA in patients with glucose >550<ref>Chebl RB, Madden B, Belsky J, et al. Diagnostic value of end tidal capnography in patients with hyperglycemia in the emergency department. BMC Emerg Med. 2016;16(1).</ref>
*Leukocytosis is common in DKA even without infection (stress response); WBC >25,000 or bandemia is more suggestive of true infection


==Management==
==Management==
[[File:DKA management.png|thumb|Algorithm for the management of diabetic ketoacidosis]]
[[File:DKA management.png|thumb|Algorithm for the management of diabetic ketoacidosis]]
*If the patient has an insulin pump, make sure it is shut off or disconnected
*If the patient has an insulin pump, shut it off and remove the subcutaneous catheter


===Volume Repletion===
===Volume Repletion===
*Administer 20-30cc/kg [[lactated ringers]] bolus during the first hour
*Administer 15-20 mL/kg/h isotonic crystalloid during the first hour (typically 1-1.5L)<ref name="ADA2024"/>
**Most important step in treatment since osmotic diuresis is the major driving force<ref name="British DKA"></ref>
**Most important step in treatment since osmotic diuresis is the major driving force
**Most adult patients are 3-6L depleted  
**Most adult patients are 3-6L depleted; aim to correct ~50% of fluid deficit in first 8-12 hours
**Increased systemic perfusion may transport insulin to previously unreached receptor sites, inhibiting ketogenesis
**[[Lactated Ringers]] is preferred over NS — may resolve DKA faster and causes less hyperchloremic acidosis<ref>Self WH, et al. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis. JAMA Netw Open. 2020;3(11):e2024982.</ref><ref>Carrillo R, et al. Balanced Crystalloid Versus Normal Saline as Resuscitative Fluid in Diabetic Ketoacidosis. Am J Emerg Med. 2022;53:180-186.</ref>
**Increased renal perfusion promotes renal hydrogen ion loss
**When blood glucose (BG) <250-300 mg/dL → add a D10 infusion at an equal rate to LR to prevent hypoglycemia while continuing insulin to clear ketones<ref>Farkas J. DKA. Internet Book of Critical Care (IBCC). https://emcrit.org/ibcc/dka/</ref>
**Use of LRs is preferred over NS <ref>Carrillo et al. Balanced Crystalloid Versus Normal Saline as Resuscitative Fluid in Diabetic Ketoacidosis. https://pubmed.ncbi.nlm.nih.gov/34986659/</ref>,<ref>Self et al. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis: A Subgroup Analysis of Cluster Randomized Clinical Trials. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772993/</ref>
**Patients can eat and drink if mental status is intact<ref>Lipatov K, et al. Early vs late oral nutrition in patients with diabetic ketoacidosis admitted to a medical intensive care unit. World J Diabetes. 2019;10(1):57-64.</ref>
**When blood sugar(BS) < 250-300 add a D10 infusion at an equal rate to the LR using a single IV line <ref>https://emcrit.org/ibcc/dka/</ref>
*Use caution in patients with [[CHF]], [[chronic kidney disease]], or ESRD — smaller boluses with frequent reassessment
**Patients can eat and drink if mental status is intact <ref>Lipatov, K. et al. Early vs late oral nutrition in patients with diabetic ketoacidosis admitted to a medical intensive care unit. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347656/</ref>


===[[Electrolyte Repletion]]===
===[[Electrolyte Repletion]]===
*Potassium (most important!)<ref>*http://emupdates.com/2010/07/15/correction-of-critical-hypokalemia/</ref>
====Potassium (Most Important!)====
**<3.5mEq/L:
*'''Check K⁺ BEFORE starting insulin. Do not give insulin until K⁺ supplementation is underway if K⁺ <3.5'''<ref>Aurora S, Cheng D, Wyler B, Menchine M. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med. 2012;30:481-4.</ref>
***Start potassium repleation: 20-30 mEq KCl to IVF/hr
{| class="wikitable"
***Do not administer insulin (to avoid worsening of hypokalemia)
|-
**>3.5mEq/L and <5.5 mEq/L:
! K⁺ Level !! Action
***Start potassium repleation: 20-30 mEq KCl to IVF/hr
|-
***May start insulin (see below)
| '''<3.5 mEq/L''' || '''Hold insulin.''' Start aggressive K⁺ repletion: 20-40 mEq KCl/hr IV. Recheck q1-2h. Start insulin only after K⁺ ≥3.5.
**>5.5 mEq/L:
|-
***Hold potassium repletion and recheck electroltyes after initiaton of insulin (see below)
| '''3.5-5.5 mEq/L''' || Start K⁺ repletion: 20-30 mEq KCl per liter of IVF. May start insulin concurrently.
*Sodium
|-
**[[Hyponatremia]]
| '''>5.5 mEq/L''' || Hold K⁺ repletion. Start insulin. Recheck K⁺ in 1-2 hours (it will fall rapidly with insulin + fluids).
***Correct for hyperglycemia
|}
****Na+ decreases by 1.6mEq/L for every 100mg/dL increase in glucose (ie pseudohyponatremia)
 
***If truly hyponatraemic, start NS 250-500ml/hr
====Other Electrolytes====
**[[Hypernatremia]]
*Sodium: Calculate corrected Na⁺ (see above). If truly hyponatremic, use NS. If hypernatremic, consider LR or half-NS.
***Consider Lactated Ringers
*[[Hypophosphatemia]]: Replete if <1.0 mg/dL (IV K₂PO₄ — has the added benefit of providing K⁺). Severe hypophosphatemia can cause cardiac/respiratory dysfunction and hemolytic anemia.
*[[Hypophosphatemia]]
*[[Hypomagnesemia]]: Replete if Mg <2.0 mg/dL (2g MgSO₄ IV over 1 hour)
**<1.0 mEq/L, start repletion:
***IV K2PO4 at 1mL/hour (contains 4.4meqK+ & 93mg phos)
***Severe hypophosphatemia can cause cardiac and respiratory dysfunction
*[[Hypomagnesemia]]
**Mg<2.0mg/DL, start repletion:
***2g MgSO4 IV over 1h


===[[Insulin]] Overview===
===[[Insulin]] Overview===
*'''Check potassium prior to insulin treatment (see above)! Do not administer insulin until potassium supplementation is underway.'''<ref>Aurora S, Cheng D, Wyler B, Menchine M. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med 2012; 30: 481-4.</ref>
*A bolus dose is NOT recommended — no benefit and may increase hypoglycemic episodes<ref>Goyal N, et al. Utility of Initial Bolus Insulin in the Treatment of Diabetic Ketoacidosis. J Emerg Med. 2010;38(4):422-7.</ref>
*A bolus dose is unnecessary and may contribute to increased hypoglycemic episodes<ref>Goyal N, Miller J, Sankey S, Mossallam U. Utility of Initial Bolus insulin in the treatment of diabetic ketoacidosis. Journal of Emergency Medicine, Vol 20:10, p30.</ref>
*Expect BG to fall by 50-100 mg/dL per hour with adequate insulin and fluids
*If the patient comes in wearing an insulin pump, turn off the pump and remove the subcutaneous catheter.
*Refractory hyperglycemia → consider unrecognized infection, inadequate fluid resuscitation, or insulin delivery failure
*Expect BS to fall by 50-100mg/dL per hr if you administer 0.1units/kg/hr of insulin
*Refractory hyperglycemia may be due to an associated infectious process contributing to the DKA


====Long-Acting (Basal) Insulin====
====Intravenous Insulin (Standard for Moderate-Severe DKA)====
*Two main practices exist: 1) Close the anion gap, then start basal insulin 2-3 hours before stopping insulin infusion, 2) Early basal insulin
*Fixed rate: 0.1 units/kg/hr (or 0.14 units/kg/hr without bolus; or 0.05 units/kg/hr per some protocols)<ref name="ADA2024"/>
**Potential benefits of early basal insulin (glargine or detemir) include protecting against erroneously stopping insulin infusion prematurely and eliminating the 2-3 hour waiting period of starting basal insulin while on IV infusion
**Fixed rate infusion has improved outcomes over variable rate<ref>Evans K. Diabetic ketoacidosis: update on management. Clin Med (Lond). 2019;19(5):396-398.</ref>
*Early basal insulin:<ref>Rao P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022;5(4):e226417. doi:10.1001/jamanetworkopen.2022.6417</ref>
*'''Do NOT stop insulin infusion until DKA has resolved''' — resolution requires clearance of ketones, not merely correction of glucose
**Glargine 0.30 U/kg SQ x 1<ref>Hsia E, Seggelke S, Gibbs J, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012;97(9):3132-3137.</ref><ref>Doshi P, Potter A, De L, Banuelos R, Darger B, Chathampally Y. Prospective randomized trial of insulin glargine in acute management of diabetic ketoacidosis in the emergency department: a pilot study. Acad Emerg Med. 2015;22(6):657-662.</ref>, '''OR'''
*Resolution criteria (2024 consensus):<ref name="ADA2024"/>
**Determine total 24 hour home dose of basal insulin and deliver that q24 hours (e.g. patient's normal home dose of glargine)<ref>Rappaport S, Endicott J, Gilbert M, Farkas J, Clouser R, McMillian W. A Retrospective Study of Early vs Delayed Home Dose Basal Insulin in the Acute Management of Diabetic Ketoacidosis. J Endocr Soc. 2019;3(5):1079-1086.</ref>
**BHB <0.6 mmol/L (preferred), AND
**Venous pH >7.3, AND
**Bicarbonate ≥18 mEq/L
**If BHB is not available, normalization of anion gap is an acceptable surrogate
*When BG <250-300 mg/dL → add D10 infusion; do NOT decrease insulin below 0.05 units/kg/hr until ketones clear
*Maintain BG between 150-250 mg/dL until resolution of acidosis


===Short-Acting [[Insulin]]===
====Subcutaneous Insulin (Appropriate for Mild DKA Only)====
====Intravenous Regimen (Short-Acting)====
''SC regimen requires rapid-acting insulin (e.g., aspart, lispro). Appropriate only for mild DKA (pH 7.25-7.3, alert, tolerating PO, able to void). Poor perfusion may impair absorption.''<ref name="ADA2024"/><ref>Umpierrez G, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873-8.</ref><ref>Griffey R, et al. The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics. Am J Emerg Med. 2023;66:14-18.</ref>
''Do not stop insulin infusion until AG normalized AND bicarb normalized, despite resolution of blood sugar. Aim of insulin regime is to correct the acidosis, not merely the hyperglycemia.''
*Initial infusion 0.1 to 0.14 units/kg/hr of insulin (or 0.05units/kg/hr per local protocol)
**Fixed Rate Insulin Infusion has improved outcomes over Variable Rate <ref>Paranthaman, K & Srinivasan, B. Fixed Rate Insulin Infusion (FRII) vs Variable Rate Insulin Infusion (VRII) in Management of Patients with Diabetic Ketoacidosis (DKA). https://www.gavinpublishers.com/article/view/fixed-rate-insulin-infusion-frii-vs-variable-rate-insulin-infusion-vrii-in-management-of-patients-with-diabetic-ketoacidosis-dka</ref><ref>Evans, K. Diabetic ketoacidosis: update on management. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771342/</ref>
*Maintain BS between 150 and 200mg/dL until resolution of acidosis
**May require IV fluids to be switched to Dextrose 10% when BS <150mg/dL
*Continue IV infusion for 2 hrs after subcutaneous insulin is begun
*Subcutaneous route (appropriate only for mild DKA and if able to eat and void urine; poor perfusion may hamper its absorption)


====Subcutaneous Regimen (Short-Acting)====
1-Hour Protocol:
''A subcutaneous (SC) regimen must use short acting insulin and follow either a 1hr or 2hr dosing protocol. Regular insulin is not effective.<ref>Umpierrez G. et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004 Aug;27(8):1873-8 [PDF http://care.diabetesjournals.org/content/27/8/1873.full.pdf]</ref>'' '''For patients who are euglycemic (glucose <250 mg/dl) at presentation (e.g. with mild gap), using standard [[Insulin#Insulin_Sliding_Scale|insulin sliding scale]] instead of this regimen.<ref>Rao P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022;5(4):e226417. doi:10.1001/jamanetworkopen.2022.6417</ref>''' <ref>Griffey R. et al. The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics. https://pubmed.ncbi.nlm.nih.gov/36775281/</ref>
*Initial: 0.3 units/kg SC, then 0.1 units/kg SC every hour
*When BG <250: add D5 0.45% NS; reduce to 0.05 units/kg/hr SC
*Target BG ~150 mg/dL until DKA resolution


'''1hr Protocol'''
2-Hour Protocol:
*Initial dose SC short acting insulin (e.g. Aspart): 0.3 units/kg [[ideal body weight]], followed by
*Initial: 0.3 units/kg SC, then 0.2 units/kg SC at 1 hour, then 0.2 units/kg SC q2hr
**0.1 units/kg SC every hour
*When BG <250: add D5 0.45% NS; reduce to 0.1 units/kg q2hr SC
**When blood glucose <250mg/dl (13.8 mmol/l), change IV fluids to D5<sub 0.45%</sub>NS and reduce SC aspart insulin to 0.05 units/kg/hr
*Target BG ~150 mg/dL until DKA resolution
**Keep glucose at 150mg/dl (11 mmol/l) until resolution of DKA.


'''2hr Protocol'''
====Transition to Basal-Bolus Insulin====
*Initial dose SC short acting insulin (e.g. Aspart): 0.3 units/kg [[ideal body weight]], followed by
*Start basal insulin (glargine) 1-2 hours BEFORE discontinuing IV insulin infusion<ref name="ADA2024"/>
**0.2 units/kg SC 1 hour later followed by Q2hr dosing
*Two approaches:
**When blood glucose <250mg/dl (13.8 mmol/l), change IV fluids to D5 0.45% saline and reduce SC insulin to 0.1 units/kg/ 2hr
**Early basal: Glargine 0.3 U/kg SC ×1 early in DKA course (protects against rebound hyperglycemia, eliminates the 1-2h overlap waiting period)<ref>Hsia E, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012;97(9):3132-7.</ref><ref>Rao P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022;5(4):e226417.</ref>
**Keep glucose at 150mg/dl (11 mmol/l) until resolution of DKA.
**Traditional: Close the anion gap / clear BHB → start basal insulin 1-2h before stopping infusion → verify patient is eating before fully transitioning


===[[Bicarbonate]]<ref>[[EBQ:Sodium Bicarbonate use in DKA]]</ref>===
===[[Bicarbonate]]===
{{EBQ Sodium Bicarbonate use in DKA conclusion}}
{{EBQ Sodium Bicarbonate use in DKA conclusion}}
*Pitfalls of sodium bicarbonate therapy in DKA (outside of last ditch efforts in severe acidemia)<ref>Nickson C. Sodium Bicarbonate and Diabetic Ketoacidosis. Jan 28, 2014. http://lifeinthefastlane.com/ccc/sodium-bicarbonate-and-diabetic-ketoacidosis/.</ref>
*Generally NOT recommended — multiple studies show no benefit in DKA resolution or time to discharge<ref name="ADA2024"/>
*Consider only if pH <6.9 (or <7.0 per some protocols) with hemodynamic instability
*Pitfalls of bicarbonate in DKA:<ref>Nickson C. Sodium Bicarbonate and Diabetic Ketoacidosis. Life in the Fast Lane. 2014.</ref>
**Paradoxical CSF acidosis
**Paradoxical CSF acidosis
**Hypokalemia from H+ and K+ shifts
**Hypokalemia from H⁺/K⁺ shifts
**Large sodium bolus
**Large sodium bolus
**Cerebral edema
**Risk of cerebral edema
**Shifts oxygen-hemoglobin dissociation curve to left, decreasing O2 delivery to tissues
**Shifts oxygen-hemoglobin dissociation curve leftward → decreased O₂ delivery


===Subsequent Management===
===Additional Management Considerations===
====Labs/Monitoring====
*VTE prophylaxis: DKA is a hypercoagulable state — consider prophylactic-dose [[heparin]] or [[enoxaparin]] (adjust for renal function) in immobilized or critically ill patients
*Glucose check Q1hr
*Infection: Treat empirically if suspected; do not wait for culture results to initiate antibiotics
*Chem 10 Q2r (then move to Q4hr)  
*Continuous telemetry: [[Hyperkalemia]] and [[hypokalemia]] are both arrhythmogenic; monitor throughout treatment
*Check pH PRN based on clinical status (eval respiratory compensation)
*Check appropriateness of [[insulin]] dose Q1hr (see below)
*Corrected Electrolytes


====Sliding Scale====
===Intubation===
*[[Insulin]] Sliding Scale to be started once patient's DKA has resolved and eating a full diet.
*'''Avoid intubation in DKA whenever possible''' — this is a critical ED pearl<ref>Farkas J. Four DKA Pearls. PulmCrit. 2014.</ref>
*Risks:
**During sedation/paralysis, loss of compensatory hyperventilation → precipitous pH drop that can cause cardiac arrest
**Severe gastroparesis in DKA → high aspiration risk
**Awake DKA patients can generally achieve greater minute ventilation than a mechanical ventilator
*If intubation is unavoidable:
**Set the ventilator to '''match the patient's pre-intubation respiratory rate and tidal volume''' (high RR, high Vt)
**Avoid paralyzing the patient if possible
**Pre-oxygenate aggressively
*See [[Intubation#Severe Metabolic Acidosis|Intubation in severe metabolic acidosis]] for more detail


===[[Intubation]]===
===Subsequent Monitoring===
*Avoid intubation unless patient cannot generate respiratory alkalosis compensation due to extreme fatigue<ref>Four DKA Pearls. May 7, 2014. http://www.pulmcrit.org/2014/05/four-dka-pearls.html</ref>
*Glucose check Q1hr (bedside POC)
*Risks associated with intubation in DKA:
*BMP Q2hr initially (then Q4hr as improving); include anion gap calculation
**During sedation/paralysis, a rise in PaCO2 can decrease pH considerably
*BHB Q2-4hr if available (preferred over anion gap for monitoring resolution)<ref name="ADA2024"/>
**Severe gastroparesis in DKA creates a significant risk for aspiration
*Check VBG pH PRN based on clinical status
**Strong DKA patients generally can achieve greater hyperventilation than mechanical ventilated patients
*Assess insulin dose adequacy Q1hr (BG should fall 50-100 mg/dL per hour)
*See [[Intubation#Severe_Metabolic_Acidosis|Intubation]] for more information
*Monitor corrected sodium trend — should be rising as glucose falls
*K⁺ with every BMP — and whenever insulin rate is changed
*Sliding scale insulin to be started once DKA has fully resolved and patient is eating a full diet


==Disposition==
==Disposition==
*Admit to higher level care (usually ICU or step-down unit initially)
*Admit to ICU or step-down: Moderate-severe DKA (pH <7.24), AMS, hemodynamic instability, significant comorbidity, need for IV insulin infusion
*Subsequent hospital discharge requires closing on anion gap and resolution of symptoms.
*Admit to monitored bed: Mild DKA on SC protocol, but requiring observation for resolution and precipitant evaluation
*Patients with mild DKA may be treated as outpatients if reliable, close follow-up available and underlying causes not requiring admission
*Consider ED treatment and discharge (rare): Only for mild DKA in a known, reliable patient with clear precipitant (e.g., insulin pump failure), DKA fully resolved before discharge (BHB <0.6 or anion gap closed, pH >7.3, bicarb ≥18, BG <200, tolerating PO, K⁺ normal), and close follow-up within 24-48 hours<ref name="ADA2024"/>
*Discharge education: Sick day rules (never stop basal insulin, check BG and ketones when ill, maintain hydration), when to seek care (persistent vomiting, BG >300, positive ketones), insulin access resources if cost is a barrier
*Schedule outpatient follow-up within 1-2 weeks if medications were changed (or within 1 month)<ref name="ADA2024"/>


==Complications==
==Complications==
*[[Cerebral Edema in DKA]]
*[[Cerebral Edema in DKA]]: More common in pediatric DKA; risk factors include excessive free water, rapid glucose correction, failure of corrected sodium to rise, and bicarbonate use
*[[Hypokalemia]]: Most dangerous iatrogenic complication — from insulin-driven intracellular K⁺ shift without adequate repletion
*Hypoglycemia: From excessive insulin without adequate dextrose supplementation
*[[ARDS]]/pulmonary edema: From aggressive fluid resuscitation, especially in patients with cardiac or renal comorbidities
*Venous thromboembolism: DKA is a prothrombotic state
*Rhabdomyolysis (rare)
*Dialysis disequilibrium-like syndrome (rapid osmolar shifts)


<div style="display:none">
<!-- SMW MedicationDose annotations for DKA medications -->
{{MedicationDose|drug=Insulin|dose=0.1 units/kg/hr IV infusion (no bolus); reduce to 0.02-0.05 units/kg/hr when BG <250|route=IV drip|context=IV insulin for moderate-severe DKA|indication=Diabetic ketoacidosis|notes=Do NOT stop until DKA resolved; no bolus recommended}}
{{MedicationDose|drug=Insulin|dose=0.3 units/kg SC initial, then 0.1-0.2 units/kg SC q1-2h|route=SC|context=SC insulin for mild DKA only|indication=Diabetic ketoacidosis|notes=Mild DKA only (pH 7.25-7.3, alert, tolerating PO); poor perfusion impairs absorption}}
{{MedicationDose|drug=Sodium bicarbonate|dose=100 mEq in 400 mL sterile water IV over 2 hours|route=IV drip|context=Severe acidosis (pH <6.9)|indication=Diabetic ketoacidosis|notes=Generally NOT recommended; consider only if pH <6.9 with hemodynamic instability}}
</div>
==See Also==
==See Also==
*[[Diabetes mellitus (main)]]
*[[Diabetes mellitus (main)]]
*[[EBQ:Sodium_Bicarbonate_use_in_DKA|Evidence Review Sodium Bicarbonate in DKA]]
*[[EBQ:Sodium Bicarbonate use in DKA|Evidence Review: Sodium Bicarbonate in DKA]]
*[[Diabetic ketoacidosis (peds)]]
*[[Diabetic ketoacidosis (peds)]]
*[[Ketonemia]]
*[[Ketonemia]]
*[[Cerebral edema in DKA]]
*[[Cerebral edema in DKA]]
*[[Hyperglycemia]]
*[[Hyperosmolar hyperglycemic state]]
*[[Alcoholic Ketoacidosis]]
*[[Chronic kidney disease]]
== Calculators ==
{{Corrected_Sodium_Calculator}}
{{Anion_Gap_Calculator}}


==External Links==
==External Links==
*[http://www.bsped.org.uk/clinical/docs/DKAcalculator.pdf British Society for Paediatric Endocrinology and Diabetes - Paediatric Diabetic Ketoacidosis]
*[https://diabetesjournals.org/care/article/47/8/1257/156808/Hyperglycemic-Crises-in-Adults-With-Diabetes-A ADA 2024 Consensus Report: Hyperglycemic Crises in Adults (Full Text)]
*[http://ddxof.com/diabetic-ketoacidosis/ DDxOf: Management of DIabetic Ketoacidosis]
*[https://emcrit.org/ibcc/dka/ IBCC - DKA Management]
*[http://ddxof.com/diabetic-ketoacidosis/ DDxOf: Management of Diabetic Ketoacidosis]


==References==
==References==

Latest revision as of 09:37, 22 March 2026

Background

This page is for adult patients. For pediatric patients, see: diabetic ketoacidosis (peds)


  • Diabetic ketoacidosis (DKA) is a life-threatening hyperglycemic emergency characterized by hyperglycemia (or euglycemia in ~10%), metabolic acidosis, and ketonemia
  • Hospital admissions for DKA have increased substantially over the past decade[1]
  • Patients in DKA are almost always K⁺ depleted despite initially normal or elevated serum K⁺
    • Extracellular shift of K⁺ occurs due to acidosis, hyperosmolality, and insulin deficiency
    • Insulin infusion drives K⁺ back intracellularly → can unmask severe total body K⁺ depletion

Epidemiology

  • Inpatient DKA mortality: approximately 0.2% in type 1 diabetes and 1.0% in type 2 diabetes[1]
  • DKA can occur in both type 1 and type 2 diabetes (up to 50% of DKA admissions are T2D in some series)
  • ~6-21% of adults with T1D present with DKA as their initial diagnosis[1]
  • Recurrent DKA is common and often driven by insulin omission due to cost, mental health, substance use, or social determinants — the ED is an opportunity to screen and connect to resources[1]

Pathophysiology

Defining features include hyperglycemia (glucose >200 mg/dL, or any glucose in a patient with known diabetes), acidosis (pH <7.3 or HCO₃ <18), and ketonemia (BHB ≥3 mmol/L)[1]

Hyperglycemia

  • Leads to osmotic diuresis and depletion of electrolytes including sodium, potassium, magnesium, calcium, and phosphorus
  • Further dehydration impairs GFR and contributes to acute kidney injury
  • Hypokalemia may inhibit insulin release
  • Euglycemic DKA (~10% of cases): glucose <200 mg/dL with metabolic acidosis and ketonemia — seen with SGLT-2 inhibitors, pregnancy, low carbohydrate intake, fasting, or recent insulin use[2]

Acidosis

  • Due to insulin deficiency → lipolysis → accumulation of ketoacids (represented by increased anion gap)
  • Compensatory respiratory alkalosis (tachypnea/hyperpnea — Kussmaul breathing)
  • Breakdown of adipose creates first acetoacetate, then conversion to beta-hydroxybutyrate (the predominant ketone in DKA)

Dehydration

  • Causes activation of RAAS in addition to osmotic diuresis
  • Average fluid deficit: 3-6 liters in adults (100 mL/kg)
  • Initial serum values for electrolytes (especially K⁺) may be higher than actual total body stores
  • Cation loss (in exchange for chloride) worsens metabolic acidosis

Clinical Features

  • May be the initial presentation of unrecognized T1DM (6-21% of adults with T1D present with DKA as first diagnosis)
  • OR symptoms/signs of an inciting precipitant (e.g. medication/dietary nonadherence, signs/symptoms of infection, insulin pump malfunction)
  • Presenting features may include:

Constitutional

    • Generally ill-appearance
    • Fatigue, weakness, malaise
    • +/- Weight loss (may be significant in new-onset T1D)

Volume Depletion

    • Polydipsia, polyuria (initially) → decreased urine output (as volume depleted)
    • Signs of dehydration: dry mucous membranes, poor skin turgor, sunken eyes, delayed capillary refill
    • Hypotension, tachycardia
    • Most adults are 3-6 liters depleted at presentation

Gastrointestinal

    • Abdominal pain — present in up to 50% of DKA; can mimic an acute abdomen (appendicitis, pancreatitis, mesenteric ischemia)
      • ED Pearl: Abdominal pain that does not improve with correction of acidosis and hydration warrants further workup for intra-abdominal pathology — do not assume it is "just DKA"
      • Abdominal pain correlates with severity of acidosis; more common with pH <7.2
    • Nausea/vomiting (present in >75% of cases)
    • Anorexia
    • Ileus / decreased bowel sounds (from electrolyte derangements and acidosis)
    • Gastroparesis — increases aspiration risk, especially if intubation is being considered

Respiratory

    • Tachypnea — compensatory for metabolic acidosis
    • Kussmaul breathing (deep, labored breathing pattern) — classic finding in moderate-severe DKA; represents maximal respiratory compensation
    • Acetone / fruity smell on breath — from exhaled ketones; may be subtle or absent; not all clinicians can detect it
    • ED Pearl: A DKA patient who is no longer tachypneic despite persistent acidosis is decompensating — respiratory compensation is failing and the patient may need emergent airway management

Neurologic

    • Altered mental status — ranges from drowsiness and lethargy to confusion, stupor, and coma
      • Severity correlates with serum osmolality more than glucose level or pH
      • AMS is present in ~15-25% of DKA patients at presentation
    • Decreased reflexes
    • Headache
    • Seizures (uncommon; more frequent in pediatric DKA)
    • Cerebral edema — significantly increases mortality, especially in children; suspect if neurologic status worsens during treatment (see Cerebral edema in DKA)

Cardiovascular

Other

    • Hypothermia — DKA patients may be normothermic or hypothermic even in the presence of infection; absence of fever does NOT exclude infection as a precipitant
    • Blurred vision (from osmotic lens swelling)
    • Muscle cramps (from electrolyte derangements)
    • Deep vein thrombosis / pulmonary embolism — DKA is a hypercoagulable state; consider VTE in patients with unexplained tachycardia, hypoxia, or chest pain disproportionate to presentation

Differential Diagnosis

Causes of DKA (Precipitants)

Search for a precipitant in every DKA patient — it changes management

Hyperglycemia

Diabetic Emergencies

Diabetes Mellitus (New or Known)

Medication/Drug-Induced

Physiologic Stress Response

  • Sepsis / critical illness (stress hyperglycemia — very common in the ED)
  • Trauma / major surgery / burns
  • Acute coronary syndrome / myocardial infarction
  • Stroke (especially hemorrhagic)
  • Pancreatitis (both a cause and consequence)
  • Shock (any etiology)
  • Pain (catecholamine surge)
  • Seizure (postictal)
  • Physiologic stress alone rarely causes glucose >200 mg/dL in non-diabetics; glucose >200 in a "stress response" should prompt evaluation for undiagnosed diabetes or prediabetes

Endocrine

Pancreatic

  • Pancreatitis (acute or chronic — destruction of islet cells)
  • Pancreatic malignancy (adenocarcinoma, neuroendocrine tumors)
  • Post-pancreatectomy
  • Cystic fibrosis-related diabetes
  • Hemochromatosis (iron deposition in pancreas — "bronze diabetes")

Toxic/Overdose

Other

  • Renal failure (chronic kidney disease, acute kidney injury — impaired insulin clearance AND insulin resistance)
  • Cirrhosis / hepatic failure (impaired glycogenolysis regulation)
  • Pregnancy (gestational diabetes, steroid administration for fetal lung maturity)
  • Parenteral nutrition (TPN, dextrose-containing fluids)
  • Post-transplant diabetes (immunosuppressants)

Complications of Diabetes (Not Causes of Hyperglycemia)

These are associated conditions that may be present alongside hyperglycemia but do not themselves cause elevated glucose:

Evaluation

Workup

Workup to confirm diagnosis, assess severity, and search for precipitating cause (e.g., infection, ACS)

  • BMP (glucose, BUN/Cr, Na⁺, K⁺, Cl⁻, HCO₃⁻, anion gap)
  • Blood glucose (and bedside point-of-care glucose)
  • Beta-hydroxybutyrate (BHB) — preferred ketone marker for diagnosis, severity assessment, and monitoring resolution; ideally point-of-care[1]
  • VBG (arterial blood gas is rarely needed)
  • Magnesium, phosphorus, calcium
  • CBC (leukocytosis is common in DKA even without infection — >25,000 or left shift more suggestive of infection)
  • ECG — evaluate for hyperkalemia/hypokalemia, ischemia, arrhythmia
  • Urinalysis — ketonuria may be a useful screen but serum BHB is preferred (see below)
  • CXR — if infection suspected
  • Blood cultures — if concern for sepsis or bacteremia
  • Lipase — if concern for pancreatitis
  • Lactate — if concern for sepsis or tissue hypoperfusion
  • Troponin — if chest pain or concern for ACS (interpret with caution in CKD)
  • Pregnancy test — in all women of childbearing age
  • HbA1c — helpful in assessing chronic glycemic control and distinguishing new-onset T1D from poorly controlled known diabetes

Diagnosis

Diagnosis is made based on the presence of acidosis AND ketonemia in the setting of diabetes[1]

2024 ADA/EASD Consensus Diagnostic Criteria

Criterion Diagnostic Threshold
Glucose >200 mg/dL (11.1 mmol/L) OR known history of diabetes (glucose cutoff removed for known diabetics)
pH <7.3 (venous)
Bicarbonate <18 mEq/L
Beta-hydroxybutyrate ≥3.0 mmol/L (preferred), or significant ketonuria if BHB unavailable

Severity Classification

Mild Moderate Severe
pH 7.25-7.30 7.00-7.24 <7.00
Bicarbonate 15-18 mEq/L 10-14.9 mEq/L <10 mEq/L
BHB 3.0-5.9 mmol/L 6.0-9.9 mmol/L ≥10.0 mmol/L
Mental status Alert Alert/drowsy Stupor/coma

Key Laboratory Pearls

  • Blood Gas: VBG is sufficient — pH difference from ABG is ±0.02 units[3][4]
  • Urinary ketones: May give a false negative later in DKA — the urine dipstick detects acetoacetate, not beta-hydroxybutyrate. As DKA worsens, the ratio shifts toward BHB, so urine ketones may paradoxically appear negative in severe DKA[5]
  • Bicarb may be normal despite DKA due to compensatory/contraction alkalosis — the elevated anion gap or BHB may be the only clues
  • Corrected sodium: Na⁺ decreases by ~1.6 mEq/L for every 100 mg/dL increase in glucose above 100 (some use 2.4 mEq/L per 100 mg/dL for glucose >400). The corrected sodium should rise as glucose falls during treatment — if it is falling, suspect excessive free water administration (risk of cerebral edema)
  • ETCO₂: An ETCO₂ ≥35 mmHg is 100% sensitive to rule out DKA; an ETCO₂ ≤21 mmHg is 100% specific for DKA in patients with glucose >550[6]
  • Leukocytosis is common in DKA even without infection (stress response); WBC >25,000 or bandemia is more suggestive of true infection

Management

Algorithm for the management of diabetic ketoacidosis
  • If the patient has an insulin pump, shut it off and remove the subcutaneous catheter

Volume Repletion

  • Administer 15-20 mL/kg/h isotonic crystalloid during the first hour (typically 1-1.5L)[1]
    • Most important step in treatment since osmotic diuresis is the major driving force
    • Most adult patients are 3-6L depleted; aim to correct ~50% of fluid deficit in first 8-12 hours
    • Lactated Ringers is preferred over NS — may resolve DKA faster and causes less hyperchloremic acidosis[7][8]
    • When blood glucose (BG) <250-300 mg/dL → add a D10 infusion at an equal rate to LR to prevent hypoglycemia while continuing insulin to clear ketones[9]
    • Patients can eat and drink if mental status is intact[10]
  • Use caution in patients with CHF, chronic kidney disease, or ESRD — smaller boluses with frequent reassessment

Electrolyte Repletion

Potassium (Most Important!)

  • Check K⁺ BEFORE starting insulin. Do not give insulin until K⁺ supplementation is underway if K⁺ <3.5[11]
K⁺ Level Action
<3.5 mEq/L Hold insulin. Start aggressive K⁺ repletion: 20-40 mEq KCl/hr IV. Recheck q1-2h. Start insulin only after K⁺ ≥3.5.
3.5-5.5 mEq/L Start K⁺ repletion: 20-30 mEq KCl per liter of IVF. May start insulin concurrently.
>5.5 mEq/L Hold K⁺ repletion. Start insulin. Recheck K⁺ in 1-2 hours (it will fall rapidly with insulin + fluids).

Other Electrolytes

  • Sodium: Calculate corrected Na⁺ (see above). If truly hyponatremic, use NS. If hypernatremic, consider LR or half-NS.
  • Hypophosphatemia: Replete if <1.0 mg/dL (IV K₂PO₄ — has the added benefit of providing K⁺). Severe hypophosphatemia can cause cardiac/respiratory dysfunction and hemolytic anemia.
  • Hypomagnesemia: Replete if Mg <2.0 mg/dL (2g MgSO₄ IV over 1 hour)

Insulin Overview

  • A bolus dose is NOT recommended — no benefit and may increase hypoglycemic episodes[12]
  • Expect BG to fall by 50-100 mg/dL per hour with adequate insulin and fluids
  • Refractory hyperglycemia → consider unrecognized infection, inadequate fluid resuscitation, or insulin delivery failure

Intravenous Insulin (Standard for Moderate-Severe DKA)

  • Fixed rate: 0.1 units/kg/hr (or 0.14 units/kg/hr without bolus; or 0.05 units/kg/hr per some protocols)[1]
    • Fixed rate infusion has improved outcomes over variable rate[13]
  • Do NOT stop insulin infusion until DKA has resolved — resolution requires clearance of ketones, not merely correction of glucose
  • Resolution criteria (2024 consensus):[1]
    • BHB <0.6 mmol/L (preferred), AND
    • Venous pH >7.3, AND
    • Bicarbonate ≥18 mEq/L
    • If BHB is not available, normalization of anion gap is an acceptable surrogate
  • When BG <250-300 mg/dL → add D10 infusion; do NOT decrease insulin below 0.05 units/kg/hr until ketones clear
  • Maintain BG between 150-250 mg/dL until resolution of acidosis

Subcutaneous Insulin (Appropriate for Mild DKA Only)

SC regimen requires rapid-acting insulin (e.g., aspart, lispro). Appropriate only for mild DKA (pH 7.25-7.3, alert, tolerating PO, able to void). Poor perfusion may impair absorption.[1][14][15]

1-Hour Protocol:

  • Initial: 0.3 units/kg SC, then 0.1 units/kg SC every hour
  • When BG <250: add D5 0.45% NS; reduce to 0.05 units/kg/hr SC
  • Target BG ~150 mg/dL until DKA resolution

2-Hour Protocol:

  • Initial: 0.3 units/kg SC, then 0.2 units/kg SC at 1 hour, then 0.2 units/kg SC q2hr
  • When BG <250: add D5 0.45% NS; reduce to 0.1 units/kg q2hr SC
  • Target BG ~150 mg/dL until DKA resolution

Transition to Basal-Bolus Insulin

  • Start basal insulin (glargine) 1-2 hours BEFORE discontinuing IV insulin infusion[1]
  • Two approaches:
    • Early basal: Glargine 0.3 U/kg SC ×1 early in DKA course (protects against rebound hyperglycemia, eliminates the 1-2h overlap waiting period)[16][17]
    • Traditional: Close the anion gap / clear BHB → start basal insulin 1-2h before stopping infusion → verify patient is eating before fully transitioning

Bicarbonate

  • No evidence supports the use of sodium bicarb in DKA, with a pH >6.9
  • However, no studies have been performed for patients with pH <6.9 and the most recent ADA guidelines recommend it for patients with pH <7.1
  • Generally NOT recommended — multiple studies show no benefit in DKA resolution or time to discharge[1]
  • Consider only if pH <6.9 (or <7.0 per some protocols) with hemodynamic instability
  • Pitfalls of bicarbonate in DKA:[18]
    • Paradoxical CSF acidosis
    • Hypokalemia from H⁺/K⁺ shifts
    • Large sodium bolus
    • Risk of cerebral edema
    • Shifts oxygen-hemoglobin dissociation curve leftward → decreased O₂ delivery

Additional Management Considerations

  • VTE prophylaxis: DKA is a hypercoagulable state — consider prophylactic-dose heparin or enoxaparin (adjust for renal function) in immobilized or critically ill patients
  • Infection: Treat empirically if suspected; do not wait for culture results to initiate antibiotics
  • Continuous telemetry: Hyperkalemia and hypokalemia are both arrhythmogenic; monitor throughout treatment

Intubation

  • Avoid intubation in DKA whenever possible — this is a critical ED pearl[19]
  • Risks:
    • During sedation/paralysis, loss of compensatory hyperventilation → precipitous pH drop that can cause cardiac arrest
    • Severe gastroparesis in DKA → high aspiration risk
    • Awake DKA patients can generally achieve greater minute ventilation than a mechanical ventilator
  • If intubation is unavoidable:
    • Set the ventilator to match the patient's pre-intubation respiratory rate and tidal volume (high RR, high Vt)
    • Avoid paralyzing the patient if possible
    • Pre-oxygenate aggressively
  • See Intubation in severe metabolic acidosis for more detail

Subsequent Monitoring

  • Glucose check Q1hr (bedside POC)
  • BMP Q2hr initially (then Q4hr as improving); include anion gap calculation
  • BHB Q2-4hr if available (preferred over anion gap for monitoring resolution)[1]
  • Check VBG pH PRN based on clinical status
  • Assess insulin dose adequacy Q1hr (BG should fall 50-100 mg/dL per hour)
  • Monitor corrected sodium trend — should be rising as glucose falls
  • K⁺ with every BMP — and whenever insulin rate is changed
  • Sliding scale insulin to be started once DKA has fully resolved and patient is eating a full diet

Disposition

  • Admit to ICU or step-down: Moderate-severe DKA (pH <7.24), AMS, hemodynamic instability, significant comorbidity, need for IV insulin infusion
  • Admit to monitored bed: Mild DKA on SC protocol, but requiring observation for resolution and precipitant evaluation
  • Consider ED treatment and discharge (rare): Only for mild DKA in a known, reliable patient with clear precipitant (e.g., insulin pump failure), DKA fully resolved before discharge (BHB <0.6 or anion gap closed, pH >7.3, bicarb ≥18, BG <200, tolerating PO, K⁺ normal), and close follow-up within 24-48 hours[1]
  • Discharge education: Sick day rules (never stop basal insulin, check BG and ketones when ill, maintain hydration), when to seek care (persistent vomiting, BG >300, positive ketones), insulin access resources if cost is a barrier
  • Schedule outpatient follow-up within 1-2 weeks if medications were changed (or within 1 month)[1]

Complications

  • Cerebral Edema in DKA: More common in pediatric DKA; risk factors include excessive free water, rapid glucose correction, failure of corrected sodium to rise, and bicarbonate use
  • Hypokalemia: Most dangerous iatrogenic complication — from insulin-driven intracellular K⁺ shift without adequate repletion
  • Hypoglycemia: From excessive insulin without adequate dextrose supplementation
  • ARDS/pulmonary edema: From aggressive fluid resuscitation, especially in patients with cardiac or renal comorbidities
  • Venous thromboembolism: DKA is a prothrombotic state
  • Rhabdomyolysis (rare)
  • Dialysis disequilibrium-like syndrome (rapid osmolar shifts)


Insulin 0.1 units/kg/hr IV infusion (no bolus); reduce to 0.02-0.05 units/kg/hr when BG <250 IV drip — Do NOT stop until DKA resolved; no bolus recommended Insulin 0.3 units/kg SC initial, then 0.1-0.2 units/kg SC q1-2h SC — Mild DKA only (pH 7.25-7.3, alert, tolerating PO); poor perfusion impairs absorption Sodium bicarbonate 100 mEq in 400 mL sterile water IV over 2 hours IV drip — Generally NOT recommended; consider only if pH <6.9 with hemodynamic instability

See Also

Calculators

Corrected Sodium

Corrected Sodium for Hyperglycemia
Parameter Value
Measured Sodium (mEq/L)
Serum Glucose (mg/dL)
Results
Corrected Na⁺ (Katz, 1.6 mEq per 100 mg/dL) mEq/L
Corrected Na⁺ (Hillier, 2.4 mEq per 100 mg/dL) mEq/L
References
  • Katz MA. Hyperglycemia-induced hyponatremia — calculation of expected serum sodium depression. N Engl J Med. 1973;289(16):843-844. PMID 4763428.
  • Hillier TA, Abbott RD, Barrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med. 1999;106(4):399-403. PMID 10225241.
  • Classic formula (Katz): Corrected Na = Measured Na + 1.6 × (Glucose − 100) / 100
  • Revised formula (Hillier): Corrected Na = Measured Na + 2.4 × (Glucose − 100) / 100 (preferred when glucose >400)


Anion Gap

Anion Gap Calculator
Parameter Value
Sodium (Na⁺) mEq/L
Chloride (Cl⁻) mEq/L
Bicarbonate (HCO₃⁻) mEq/L
Albumin (g/dL) — optional, for correction
Results
Anion Gap mEq/L
Corrected AG (for albumin) mEq/L
Delta-Delta Ratio (ΔAG / ΔHCO₃)
Interpretation
AG <12 Normal anion gap — Consider non-AG metabolic acidosis (HARDUPS mnemonic).
AG ≥12 Elevated anion gap — Consider MUDPILES: Methanol, Uremia, DKA, Propylene glycol, Isoniazid/Iron, Lactic acidosis, Ethylene glycol, Salicylates.
Delta-Delta Ratio
<1 Concurrent non-AG metabolic acidosis (mixed).
1–2 Pure anion gap metabolic acidosis.
>2 Concurrent metabolic alkalosis (or pre-existing elevated HCO₃).
References
  • Kraut JA, Madias NE. Serum anion gap: its uses and limitations in clinical medicine. Clin J Am Soc Nephrol. 2007;2:162-174. PMID 17699401.
  • Fenves AZ et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid). Proc (Bayl Univ Med Cent). 2006;19:364-367.

External Links

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47(8):1257-1275.
  2. Peters AL et al. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687-1693.
  3. Kelly AM et al. Review Article – Can Venous Blood Gas Analysis Replace Arterial in Emergency Medical Care. Emerg Med Australas. 2010;22:493-498.
  4. Ma OJ et al. Arterial Blood Gas Results Rarely Influence Emergency Physician Management of Patients with Suspected Diabetic Ketoacidosis. Acad Emerg Med. 2003;10(8):836-41.
  5. Stojanovic V, Ihle S. Role of beta-hydroxybutyric acid in diabetic ketoacidosis: A review. Can Vet J. 2011;52(4):426-430.
  6. Chebl RB, Madden B, Belsky J, et al. Diagnostic value of end tidal capnography in patients with hyperglycemia in the emergency department. BMC Emerg Med. 2016;16(1).
  7. Self WH, et al. Clinical Effects of Balanced Crystalloids vs Saline in Adults With Diabetic Ketoacidosis. JAMA Netw Open. 2020;3(11):e2024982.
  8. Carrillo R, et al. Balanced Crystalloid Versus Normal Saline as Resuscitative Fluid in Diabetic Ketoacidosis. Am J Emerg Med. 2022;53:180-186.
  9. Farkas J. DKA. Internet Book of Critical Care (IBCC). https://emcrit.org/ibcc/dka/
  10. Lipatov K, et al. Early vs late oral nutrition in patients with diabetic ketoacidosis admitted to a medical intensive care unit. World J Diabetes. 2019;10(1):57-64.
  11. Aurora S, Cheng D, Wyler B, Menchine M. Prevalence of hypokalemia in ED patients with diabetic ketoacidosis. Am J Emerg Med. 2012;30:481-4.
  12. Goyal N, et al. Utility of Initial Bolus Insulin in the Treatment of Diabetic Ketoacidosis. J Emerg Med. 2010;38(4):422-7.
  13. Evans K. Diabetic ketoacidosis: update on management. Clin Med (Lond). 2019;19(5):396-398.
  14. Umpierrez G, et al. Treatment of diabetic ketoacidosis with subcutaneous insulin aspart. Diabetes Care. 2004;27(8):1873-8.
  15. Griffey R, et al. The SQuID protocol (subcutaneous insulin in diabetic ketoacidosis): Impacts on ED operational metrics. Am J Emerg Med. 2023;66:14-18.
  16. Hsia E, et al. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012;97(9):3132-7.
  17. Rao P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022;5(4):e226417.
  18. Nickson C. Sodium Bicarbonate and Diabetic Ketoacidosis. Life in the Fast Lane. 2014.
  19. Farkas J. Four DKA Pearls. PulmCrit. 2014.